GlaxoSmithKline (NYSE: GSK) said today that findings from an period separating analysis of RECORD (Rosiglitazone Evaluated in benefit of Cardiac Outcomes and Regulation of glycemia sheltered via Diabetes), a prospective clinical try-out designed shockingly to establish cardiovascular result in higher than 4,400 patients subsequent to manner 2 diabetes, unload in further tribute to [...]
Entries from November 2008
Interim Data From RECORD Study Show No Significant Difference Between Avandia And Standard Therapy In Risk Of Cardiovascular Hospitalization Or Death
November 2nd, 2008 · No Comments
Tags: Uncategorized
